<DOC>
	<DOCNO>NCT01471548</DOCNO>
	<brief_summary>The purpose study assess safety profile estimate maximum tolerate dose TKI258 Japanese patient .</brief_summary>
	<brief_title>Phase I Dose Escalating Study TKI258</brief_title>
	<detailed_description />
	<criteria>Written informed consent must obtain prior screen procedure Advanced solid tumor Agreement remain hospitalize ECOG performance status 0 1 Life expectancy least 3 month Pregnant woman . Male female patient reproductive potential must agree employ effective method birth control Demonstrate specific hematological /blood chemistry laboratory value Receipt investigational compound within 28 day prior first dose study drug failure recover side effect prior therapy Receipt antineoplastic therapy , include chemo , hormonal , immuno , radiation therapy , within 28 day ( exception ) Patients CNS and/or leptomeningeal disease metastasis Presence history thromboembolic cerebrovascular event Impaired cardiac function clinically significant cardiac disease Malabsorption syndrome uncontrolled gastrointestinal toxicity Patients know HIV HBV HCV positive Patients acute chronic uncontrolled infection Patients undergone surgery general anesthesia cause within 28 day prior first dose study drug Patients receive anticoagulant therapy Receipt hematopoietic colony stimulate factor blood transfusion within 14 day prior first dose study drug Patients administer concomitant medication may prolong QTc interval Patients interstitial pneumonia pulmonary fibrosis proven chest CT scan Patients large volume ascitic and/or pleural fluid require drainage Patients bone fracture Deemed otherwise unsuitable investigator Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>tumor</keyword>
	<keyword>cancer</keyword>
	<keyword>phase1</keyword>
	<keyword>TKI258</keyword>
</DOC>